

Is There Value In Surgery For Adult Spinal Deformity?

Shay Bess, MD
Denver International Spine Center
Denver, CO

Selby Spine Conference
February 2018
Park City, UT



Disclosures Shay Bess


- Consulting= Allosource, K2M
- Royalties= Pioneer Spine, K2M
- Research support= Depuy/Synthes, EOS Medtronic, K2M, Nuvasive, Orthofix, Globus
- Scientific advisory board= Allosource

Value In Surgery For ASD




Value ASD Surgery= Bad and Ugly

- ASD surgery expensive
 - McCarthy, ISSG TSJ 2014
 - Mean 4.8 years f/u (n=415)
- Bad
 - Mean total hospital costs= \$120,394
 - Primary ASD surgery=\$103,143
 - OR costs=\$70,514 (59% costs)
 - CMS reimbursable= \$65,000 (54%)
- Ugly
 - Readmissions (29%)= \$67,262
 - Complications
 - Smith, ISSG JNS 2017=78% 3CO
 - Sorocenu ISSG Spine 2015= 31% implant; 52% treated surgically
 - Sorocenu ISSG Spine 2015= 27% minimum 1 medical complication




Value ASD Surgery= Do Bad and Ugly Win?

- Value
 - the monetary worth of (something):
 - the importance, worth, or usefulness of something
- Questions
 - Is ASD important?
 - Are there treatment alternatives?
 - Do alternatives work?
 - Can we improve on current state? Variance
 - McCarthy, ISSG TSJ 2014
 - Physician preference=largest determinant OR costs



Is ASD Important?

- ISSG Spine 2016
- Quantify ASD disease impact
 - ASD cohort (n=497)
 - No prior surgery
- ASD SF-36 PCS, MCS
 - Population norm
 - Generational norms
 - Chronic disease
- ASD vs. U.S. generational norms: PCS
 - <25th percentile all generations
 - More rapid decline than U.S. general



ASD and Disability

- ASD no other comorbidities vs U.S.
 - <25th percentile
 - All ASD generations (except 18-24 yr)
 - More rapid decline than U.S. general
- ASD vs. US Healthy and Disease Norms
 - >1 MCID back pain/sciatica
 - >1 MCID Hypertension
- Similar
 - Cancer
 - Diabetes
 - Heart disease

Age Group	US Norm	ASD
Total	~45	~40
18-24 years	~45	~40
25-34 years	~45	~40
35-44 years	~45	~40
45-54 years	~45	~40
55-64 years	~45	~40
65-74 years	~45	~40
>75 years	~45	~40

Category	Score
Healthy Pop./General Pop.	~55
ASD	~40
Cancer	~40
Diabetes	~40
Heart Disease	~40
RA	~40

ASD Deformity Type and Disability

- ASD heterogenous
 - Type (sagittal, coronal, mixed)
 - Location (thoracic, lumbar, etc)
 - Severity
- Cohort division SRS-Schwab Classification
- PCS worsens
 - Curve location
 - Sagittal malalignment

ASD Type, Severity and Disease Correlates

Scenario	ASD PCS	Disease 1 PCS	Disease 2 PCS
US general	~45	~45	~45
ASD total vs MT curve vs cancer and diabetes	40.9	~40	~40
ASD total vs US total and back pain	45.5	~45	~45
L curve vs OA and heart disease	36.7	~36	~36
SVA >5 vs 25th OA and 25th RA	30.4	~30	~30
SVA >10 vs 25th limited vision and 25th lung disease	28.5	~28	~28
L curve + SVA >5 vs 25th limited use arms legs	29.3	~29	~29
L curve + SVA >10 = No comparable disease value	24.7	~24	~24

Materials and Methods

- Data source
 - ISSG database
 - Multi-center, prospective, ASD
- Database inclusion criteria
 - Age >18 years
 - Minimum one: scoliosis >20°, SVA >5cm, PT>25°, TK >60°
- Study inclusion criteria
 - Surgery for ASD
 - PSF ≥4 levels
 - Minimum two year follow-up
- ASD type
 - SRS-Schwab ASD Classification

Coronal Curve Types	Sagittal Modifiers
T: Thoracic only with lumbar curve < 30°	PI minus LL 0 : within 10° + : moderate 10-20° ++ : marked >20°
L: TL / Lumbar only with thoracic curve < 30°	Global Alignment 0 : SVA < 4cm + : SVA 4 to 9.5cm ++ : SVA > 9.5cm
D: Double Curve with T and TL/L curves > 30°	Pelvic Tilt 0 : PT < 20° + : PT 20-30° ++ : PT > 30°
N: No Major Coronal Deformity all coronal curves < 30°	


Materials and Methods

- Percent change ASD type
- Preoperative vs. last follow up
 - NRS back and leg pain
 - Specific domains
 - SF-36
 - SRS-22r
- Domains >1 SD generational norm
 - Most impacted domains
 - Return to "normal"

PROM Domains
SF-36
Physical function
Bodily pain
Role physical
General health
Vitality
Social function
Role emotional
Mental health
SRS-22r
Pain
Activity
Appearance
Mental health


Results: All ASD Patients (n=377)

- All ASD
 - N= 377/582 (65%)
 - Age 57.8 years
 - ASA grade= 2.4
 - Scoliosis= 42.6°
 - SVA= 63.9mm
 - PSF= 11.7 levels
- Pain improvement
 - Back= 44%
 - Leg= 39%
- Self-image= 61%
- Function improvement
 - Physical= 30%
 - Social= 35%




SRS ASD Type Distribution

Type	Count
All	377
Thoracic	19
Lumbar	59
Double	64
Sagittal	97
Mixed	138




Back & Leg Pain, SRS-22r Domains


Domain	Preop	Postop
Back pain	7.0	3.0
Leg pain	4.6	2.4
Self-image	3.6	1.4




SF-36 Domains

Domain	Preop	Postop
Physical function	30.8	37.2
Social function	36.2	42.6
Mental health	43.5	49.3







Results: Mixed ASD (n=138)

- Mixed ASD
 - Age 63 years
 - ASA grade= 2.5
 - Scoliosis= 48.8°
 - SVA= 103.7mm
- Pain improvement
 - Back= 49%
 - Leg= 48%
- Function improvement
 - Physical= 40%
 - Social= 40%
 - Mental= 22%
- Self-image= 68%

Back & Leg Pain, SRS-22r Domains

Domain	Preop	Postop
Back pain	7.3	3.7
Leg pain	5.5	2.8
Self-image	2.3	3.5

SF-36 Domains

Domain	Preop	Postop
Physical function	27.5	36.4
Social function	34.7	42.5
Mental health	43.3	48.6

Results: Mixed ASD Generational Norm

Second worst returns to "normal" (behind Sagittal cohort)

Preop percent >1SD from generational norm (Blue bars)
Postop percent >1SD from generational norm (Red bars)
Improvement from pre to postop (Green bars)

Domain	Preop % >1SD	Postop % >1SD	Improvement %
SF-36 PF	78.3	42	36.3
SF-36 BP	85.5	41.3	44.2
SF-36 MH	48.6	26.8	21.8
SF-36 SF	73.2	47.1	26.1
SRS-22 SI	95.5	52.3	43.2

Cost-Effectiveness ASD Treatment

- ASLS I Study (Bridwell, et al)
- Multi-Centered Prospective Trial
- Lumbar scoliosis >30 +
 - SRS-22r ≤ 4.0 (pain, function, self-image)
 - And/or ODI ≥ 20
- Randomized cohort (RC; n=63)
- Observational cohort (OB; n=223)
- 90% follow up 4yrs
- Results
 - Intent to treat: OP= NON (RC only)
 - As treated: OP>NON (RC+OB)
 - OP vs NON equivalent Incremental Cost Effectiveness Ratio (ICER) benefit at 2 years

Randomized Patients Intent to Treat

Randomized and Observational Study Patients

Randomized and Observational Study Patients

Cost-Effectiveness ASD Treatment

- ASLS I Study (Bridwell, et al)
- Incremental Cost Effectiveness Ratio (ICER) 2 years; OP =NON
- Operative group
 - mean total costs=\$110,023 (\$84,101 direct, \$25,922 indirect)
 - QALY gain
 - ODI= 0.08 (SD 0.08)
 - SF-12= 0.10 (SD 0.12)
- NON group
 - mean total cost = \$17,565 (\$9,289 direct, \$8,276 indirect)
 - QALY gain
 - ODI= 0.01 (SD 0.05)
 - SF-12=0.02 (SD 0.10)
- OP= greater benefit
- Cost/QALY gain equal

Cost-Effectiveness ASD Treatment

- Problems ASLS I Study
- Impact of as treated analysis
- Crossovers (RC)
 - OP to NON=6
 - NON to OP= 23
 - Worse preop
 - Better postop
- Result
 - ASLS II not renewed by NIH
 - No difference OP vs NON

	Randomized (n=53)	% Per Arm	Observational (n=223)	% Per Arm
Operative to Nonoperative	6	20%	0	0%
Nonoperative to Operative	23	70%	20	18%
Total	29	46%	20	9%



Treatment Assigned	Operative (n=30)		Nonoperative (n=33)			
Treatment Received	Operative (n=24)	Nonoperative (n=6)	p value	Nonoperative (n=10)	Operative (n=23)	p value
SRS-22r Subscore	3.1 (0.5)	3.3 (0.4)	0.31	3.4 (0.5)	2.9 (0.5)	0.02
ODI score	33.7 (15.5)	33.3 (14.1)	0.92	30.2 (17.0)	45.3 (14.3)	0.02
Sagittal Balance (mm)	32.2 (36.7)	34.0 (32.3)	0.63	23.1 (31.0)	59.2 (44.8)	0.02
Age at Enrollment (yrs)	59.5 (9.5)	64.5 (8.2)	0.19	62.7 (9.4)	61.9 (9.6)	0.89

Cost-Effectiveness ASD Treatment

- Needs/aims ASLS II= 8-10 year f/u
- Continue OP vs NON ICER
 - Durability treatment
 - Revisions= drive down OP cost effectiveness
 - Adverse events= drive down OP cost effectiveness
 - Decline function OP vs NON
- Predictive modeling patient characteristics
 - Revisions
 - Adverse events
- Partnership
 - SRS and ISSG
 - 5 industry partners
 - ASLS II through completion

Conclusions

- Value ASD surgery
- ASD important
 - Impactful quality of life
- Surgery
 - Improve HRQOL
- Nonoperative care
 - Minimal improvement
- ASD disability discrepant
 - Patient and deformity type
- Problem to resolve= variance
 - Operative costs; Implant and biologics
 - Outcomes
 - Complications
- Role of predictive analytics
 - Ames, ISSG, ESSG
 - Models 90% accuracy
 - MCID, QALY at 2 years, catastrophic direct cost (>100K)

Preoperative Prediction of Cost and Catastrophic Cost (CC) in Adult Spine Deformity (ASD) Surgery: Feasibility Analysis of Predictive Analytics to Establish 90 Day Bundled Payments
 Miguel Serra, PhD, Michael Kelly, MD, Justin S. Smith, MD, PhD, Ferzan Pellissé, MD, Ahmed Alaraj, MD, Emre Acaroglu, Javier Sánchez Pérez-Guerra, MD, Frank Kienast, MD, Ibrahim Oezel, MD, Samrat Veramani, MBBS, PhD, Rick Hostin, MD, Jeffrey L. Gum, MD, Corina C. Zipporatos, MD, Virginia Lefkoe, PhD, Frank Schwab, MD, Christopher I. Shaffley, MD, Douglas Burton, MD, Shay Beers, MD, Christopher P. Ames, MD, ESSG, ISSG.

Thank You



